Sun Pharma Advanced Research Company Ltd (SPRC)

Currency in INR
134.32
+0.63(+0.47%)
Closed·
SPRC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
132.12135.27
52 wk Range
109.30204.40
Key Statistics
Bid/Ask
133.68 / 134.00
Prev. Close
133.69
Open
132.5
Day's Range
132.12-135.27
52 wk Range
109.3-204.4
Volume
274.83K
Average Volume (3m)
4.7M
1-Year Change
-1.9848%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SPRC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2,000.00
Upside
+1,388.98%
Members' Sentiments
Bearish
Bullish
ProTips
Not profitable over the last twelve months
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

Sun Pharma Adv. Research Company Profile

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Employees
316
Market
India

Compare SPRC to Peers and Sector

Metrics to compare
SPRC
Peers
Sector
Relationship
P/E Ratio
−16.2x39.9x−0.5x
PEG Ratio
−0.520.000.00
Price/Book
−12.6x1.1x2.6x
Price / LTM Sales
81.7x1.6x3.3x
Upside (Analyst Target)
-17.8%47.0%
Fair Value Upside
Unlock−3.5%5.7%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2,000.00
(+1,388.98% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Feb 09, 2026
EPS / Forecast
-2.48 / --
Revenue / Forecast
84.50M / --
EPS Revisions
Last 90 days

People Also Watch

1,829.10
NARY
-0.42%
164.66
PIRM
+0.37%
549.450
HCPR
-4.34%
625.90
ATRD
+0.85%
470.65
TNSL
+1.64%

FAQ

What Is the Sun Pharma Adv. Research (SPRC) Share Price Today?

The live Sun Pharma Adv. Research share price today is 134.32

What Stock Exchange Does Sun Pharma Adv. Research (SPRC) Trade On?

Sun Pharma Adv. Research is listed and trades on the India National Stock Exchange.

What Is the Ticker (Stock Symbol) for Sun Pharma Adv. Research?

The stock symbol (also called a 'ticker') for Sun Pharma Adv. Research is "SPRC."

What Is the Current Sun Pharma Adv. Research Market Cap?

As of today, Sun Pharma Adv. Research market capitalisation is 43.59B.

What Is Sun Pharma Adv. Research's (SPRC) Earnings Per Share (TTM)?

The Sun Pharma Adv. Research EPS is currently -8.25 (Trailing Twelve Months).

Is SPRC a Buy or Sell From a Technical Analyst Perspective?

Based on today's Sun Pharma Adv. Research moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Sun Pharma Adv. Research Stock Split?

Sun Pharma Adv. Research has split 2 times. (See the SPRC stock split history page for full effective split date and price information.)

How Many Employees Does Sun Pharma Adv. Research Have?

Sun Pharma Adv. Research has 316 employees.

What is the current trading status of Sun Pharma Adv. Research (SPRC)?

As of 17/02/2026, Sun Pharma Adv. Research (SPRC) is trading at a price of 134.32, with a previous close of 133.69. The stock has fluctuated within a day range of 132.12 to 135.27, while its 52-week range spans from 109.30 to 204.40.

What Is Sun Pharma Adv. Research (SPRC) Price Target According to Analysts?

The average 12-month price target for Sun Pharma Adv. Research is INR2,000.00, with a high estimate of INR2000 and a low estimate of INR2000. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +1,388.98% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.